The FDA granted approval for lasmiditan on October 11, 2019. This approval marked the introduction of lasmiditan as a novel treatment option for the acute management of migraine attacks in adults, with or without aura.

This trial assesses SCB-1019, Clover’s bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate, developed using the company’s proprietary Trimer-Tag vaccine technology platform.

The FDA approved Beovu on October 7, 2019, for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Spyre Therapeutics Begins Phase 1 Trial with Initial Doses of SPY001, a New Long-acting anti-α4β7 Antibody, for Inflammatory Bowel Disease Treatment.

The FDA approved trifarotene on October 4, 2019, for the treatment of acne vulgaris. It is marketed under the brand name Aklief.

FDA has approved SKYRIZI® (risankizumab-rzaa) for treating ulcerative colitis, broadening AbbVie’s inflammatory bowel disease treatment options.

Tenapanor, marketed under the brand names Ibsrela and Xphozah, has been approved by the FDA for the treatment of irritable bowel syndrome with constipation (IBS-C) and for lowering phosphorus levels in the blood in adults with kidney disease.

Sobi revealed that the European Commission has approved the Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa) for the treatment and prevention of bleeding episodes and perioperative prophylaxis in patients with haemophilia A.

The U.S. Food and Drug Administration (FDA) approved lefamulin on August 19, 2019, making it the first pleuromutilin antibiotic available for systemic administration in humans.

6.17-6.23 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

The FDA first approved upadacitinib on August 16, 2019, for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to methotrexate or other similar medications.

What is the structure of YL202/BNT326, and why is it exhibiting such high toxicity?